CN116745318A - 用于阿片样物质治疗的抗体 - Google Patents

用于阿片样物质治疗的抗体 Download PDF

Info

Publication number
CN116745318A
CN116745318A CN202180085311.0A CN202180085311A CN116745318A CN 116745318 A CN116745318 A CN 116745318A CN 202180085311 A CN202180085311 A CN 202180085311A CN 116745318 A CN116745318 A CN 116745318A
Authority
CN
China
Prior art keywords
seq
gly
cys
ala
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180085311.0A
Other languages
English (en)
Chinese (zh)
Inventor
基姆·D·扬达
保罗·T·布雷默
周斌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of CN116745318A publication Critical patent/CN116745318A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Addiction (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180085311.0A 2020-11-10 2021-11-08 用于阿片样物质治疗的抗体 Pending CN116745318A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063111699P 2020-11-10 2020-11-10
US63/111,699 2020-11-10
PCT/US2021/058459 WO2022103700A1 (en) 2020-11-10 2021-11-08 Antibodies for opioid treatments

Publications (1)

Publication Number Publication Date
CN116745318A true CN116745318A (zh) 2023-09-12

Family

ID=81601678

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180085311.0A Pending CN116745318A (zh) 2020-11-10 2021-11-08 用于阿片样物质治疗的抗体

Country Status (10)

Country Link
US (1) US20230399418A1 (https=)
EP (1) EP4244256A4 (https=)
JP (1) JP7839789B2 (https=)
KR (1) KR20230107301A (https=)
CN (1) CN116745318A (https=)
AU (1) AU2021377609A1 (https=)
CA (1) CA3200523A1 (https=)
IL (1) IL302673A (https=)
MX (1) MX2023005032A (https=)
WO (1) WO2022103700A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3267132A1 (en) * 2022-09-09 2024-03-14 Regents Of The University Of Minnesota ANTIBODIES DIRECTED AGAINST FENTANYL AND ITS ANALOGUES AND THEIR METHODS OF USE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200808822A (en) * 2006-04-14 2008-02-16 Amgen Inc Erythropoietin receptor agonists
WO2013095091A2 (en) * 2011-11-17 2013-06-27 Aimm Therapeutics B.V. Rsv g protein specific antibodies
AU2017345786B2 (en) * 2016-10-21 2024-08-01 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
WO2018140821A1 (en) * 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
EP3880698A4 (en) * 2018-11-14 2022-11-30 RubrYc Therapeutics, Inc. MANIPULATED CD25 POLYPEPTIDES AND USES THEREOF

Also Published As

Publication number Publication date
WO2022103700A1 (en) 2022-05-19
MX2023005032A (es) 2023-05-16
KR20230107301A (ko) 2023-07-14
US20230399418A1 (en) 2023-12-14
EP4244256A4 (en) 2024-12-25
AU2021377609A1 (en) 2023-06-08
IL302673A (en) 2023-07-01
CA3200523A1 (en) 2022-05-19
JP2023548603A (ja) 2023-11-17
AU2021377609A9 (en) 2024-09-26
JP7839789B2 (ja) 2026-04-02
EP4244256A1 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
US12122837B2 (en) Oncostatin M receptor antigen binding proteins
EP3689370B1 (en) Anti-gdf15 antibodies
CN114805575B (zh) 人源化抗cd73抗体
JP2022160404A (ja) ヒトｉｌ－４受容体に対する高親和性ヒト抗体
EP2115003B1 (en) Human antibodies to human delta like ligand 4
EP2935330B1 (en) Anti-notch3 antibodies
EP3518973A1 (en) Neutralizing antibodies to the alpha v beta 8 integrin complex for immunotherapy
CN113412124A (zh) Baff-r双特异性t细胞衔接子抗体
CN114729053A (zh) 一种4-1bb结合蛋白及其应用
KR20180084045A (ko) 비형 간염 표면 항원에 대한 항체 및 그의 용도
JP7094329B2 (ja) 低悪性度漿液性癌におけるｈｅｒ３阻害
CN116745318A (zh) 用于阿片样物质治疗的抗体
TW202108631A (zh) 一種抗ｃｄ４７抗原結合蛋白及其應用
TW200911835A (en) Methods and compositions for inducing apoptosis in cancer cells
RU2841257C1 (ru) Антитела для лечения опиоидной зависимости
KR20230135627A (ko) 항-PDGF-b 항체 및 폐동맥 고혈압 (PAH)을 치료하기 위한 사용 방법
WO2024109709A1 (en) Ph-dependent anti-egfr antibodies for treatment of solid tumors
WO2024259273A2 (en) Mhc class i chain-related protein a (mica)-specific antibodies and uses thereof
WO2025207820A2 (en) Anti-ephrin b2 antibodies and methods of use
KR20260046391A (ko) 항-ror1 단백질 항체 및 이의 접합체
WO2026013632A1 (en) Anti-nectin-4 antibodies and uses thereof
HK40072994A (en) Oncostatin m receptor antigen binding proteins
HK40108780A (en) Oncostatin m receptor antigen binding proteins
HK40036205A (en) Anti-cd25 for tumour specific cell depletion
HK40038006A (en) Anti-cd25 for tumour specific cell depletion

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination